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Genome engineering and modification, in which particular chromosomal loci are precisely altered, 
holds great therapeutic potential, particularly in the area of cancer immunotherapy.  In this context, 
endogenous genes must be disrupted (and additional exogenous genes must be inserted) into 
patient-derived primary hematopoietic cells such as T-cells or stem cells to create cells with the 
weaponry to attack specific cancer cell types.  A variety of genome engineering systems are now 
available, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs), CRISPR/Cas9 endonucleases, and meganucleases.  Each system has unique 
advantages and disadvantages, and none are currently ideal for in vivo therapeutic 
use.  Meganucleases hold great promise for gene targeting, but have not been widely used for 
genome engineering as they are very difficult to optimize to target specific target sequences. 
As reported in Proceedings of the National Academy of Sciences, staff scientist Dr. Ryo Takeuchi 
and colleagues in the laboratory of Dr. Barry Stoddard (Basic Sciences Division) set out to develop 
an efficient scheme for engineering the DNA recognition specificities of meganucleases.  This was a 
daunting task given that the DNA binding surface of meganucleases spans up to 50 amino acids that 
contact approximately 22 base pairs of DNA.   
"Traditional methods of protein engineering and selection are generally insufficient for 
reprogramming such an extensive molecular interface, because the number of possible 
combinations of amino acids across such an extensive interface is many orders of magnitude 
greater than what can usually be produced and sampled in such experiments," said Dr. 
Stoddard.  "The methods exploited in the paper allow us to increase our 'sampling frequency' of 
protein variants by up to 1000-fold, while also applying pressure for highly active and stable 
nucleases." 
The authors computationally randomized key amino acid positions within meganuclease sequences 
and constructed libraries of DNA molecules coding for these variants.  To screen these variant 
meganucleases, the authors used a modified in vitro compartmentalization (IVC) system.  In this 
system, DNA fragments encoding both a meganuclease variant and a target site are individually 
expressed in droplets containing transcription/translation reagents.  Thus, in each droplet, an 
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endonuclease is only able to cleave a target site on the same molecule as its own gene, allowing 
confident assignment of cleavage activity to the corresponding meganuclease.  Multiple rounds of 
IVC were performed with increasing stringency, yielding seven final variant meganucleases. 
The researchers next tested their IVC-identified variant meganucleases for cleavage in living cells 
using a bacterial cleavage assay.  In this approach, meganucleases are expressed in bacterial cells 
along with a reporter plasmid containing a toxic gene and a meganuclease target site.  Cleavage 
leads to elimination of the plasmid and cell survival.  All final IVC-selected meganucleases 
substantially increased bacterial cell survival, indicating their in vivo effectiveness. 
The authors next tested the efficacy of their meganucleases by expressing each enzyme in HEK293 
cells and assessing the accumulation of small insertions and deletions (indels).  They found indels at 
the endogenous target site for each meganuclease 2.5-34% of the time.  The authors next fused 
each enzyme to a TAL effector domain (megaTAL), which increased meganuclease cleavage 
efficiency through increased DNA binding specificity.  Additionally, co-expression of two MegaTALs 
was sufficient to generate deletion of a specified chromosomal locus. 
The exquisite sequence specificity of meganucleases, particularly in the context of megaTALs, may 
be especially advantageous for therapeutic genome editing applications, which require exceptionally 
high sequence specificity to avoid deleterious off-target effects.  Indeed, future work in this area will 
focus on the application of engineered meganucleases and megaTALs to disease-relevant 
systems.  Said Dr. Stoddard, "the biggest areas for new questions and experiments following this 
work are (1) continued examination and addition of new meganuclease scaffolds to our toolkit of 
genome editing nucleases, and (2) demonstration of efficient genome editing (and in particular, 
recombinational gene modification) in primary, patient-derived human cells (as opposed to artificial 
cell lines)." 
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Image provided by Dr. Barry Stoddard 
Schematic depiction of in vitro compartmentalization. A DNA fragment containing both a 
meganuclease gene (grey box) and a meganuclease target site (green boxes) is compartmentalized 
with in vitro transcription and translation reagents, allowing for synthesis of each meganuclease 
variant, within liquid droplets. Following successful cleavage, an adapter can be ligated to the 
cleaved target site, allowing identification of the effective variant meganuclease by PCR with an 
adapter-specific primer (red arrow) and a primer common to all DNA fragments (black arrow). 
 
